Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic immunotherapy for house dust mite allergic rhinitis
TCTR20220725001Phase 2Unknown
- Sponsor
- Phramongkutklao Hospital
- Start
- Apr 2022
- Countries
- 1
01
Overview
A Phase 2 trial of house dust mite allergen-specific immunotherapy in allergic rhinitis (AR), sponsored by Phramongkutklao Hospital. Status: unknown.
02
Drugs
house dust mite allergen-specific immunotherapy
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on TCTR20220725001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220725001.